Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 647 press releases before 2018
-
Faslodex receives EU approval as first-line therapy for advanced breast cancer
-
Kyntheum approved in the EU for the treatment of adults with moderate-to-severe plaque psoriasis
-
Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer
-
AstraZeneca presents new data underpinning safety profile and real-world CV outcomes of Farxiga at ADA 2017
-
AstraZeneca to present scientific advances in cardiovascular and metabolic diseases at 2017 ADA Scientific Sessions
-
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig
-
Lynparza significantly reduces the risk of disease worsening or death in patients with BRCA-mutated metastatic breast cancer
-
AstraZeneca appoints Professor Nazneen Rahman to its Board of Directors and Science Committee
-
AstraZeneca delivers new data on expanding portfolio of cancer medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rob Skelding
Director Global Media Relations (Oncology)
+44 203 749 5821
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
